About
Vogenx, Inc.
Vogenx, Inc. operates as a clinical-stage drug development company that develops therapeutics for metabolic including post-bariatric hypoglycemia, or PBH, and gastroparesis. Its products include drugs, such as Mizagliflozin and VGX-2857.
It also offers VGX-001, a human monoclonal antibody for the treatment of type 1 diabetes (T1D). It caters to healthcare providers, physicians and third-party payors in the United States. The company was incorporated in 2021 and is based in Raleigh, North Carolina.
Vogenx, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:VOGX
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | $32.22 | $34.00 | $27.37 | $33.63 | $33.63 | +1.41 | 135,900 |
| 2026-08-26 | $31.88 | $35.00 | $28.20 | $32.88 | $32.88 | +1.00 | 266,600 |
| 2026-08-25 | $31.04 | $35.50 | $30.80 | $31.53 | $31.53 | +0.49 | 136,000 |
| 2026-08-24 | $29.34 | $35.00 | $26.20 | $30.73 | $30.73 | +1.39 | 410,000 |
| 2026-08-21 | $23.90 | $29.64 | $23.58 | $29.52 | $29.52 | +5.62 | 428,200 |
| 2026-08-20 | $23.09 | $24.31 | $20.68 | $23.65 | $23.65 | +0.56 | 125,500 |
| 2026-08-19 | $19.75 | $25.68 | $18.87 | $23.16 | $23.16 | +3.41 | 577,100 |
| 2026-08-18 | $18.63 | $20.01 | $17.51 | $19.75 | $19.75 | +1.12 | 776,200 |
| 2026-08-17 | $14.80 | $16.30 | $14.80 | $15.75 | $15.75 | +0.95 | 32,000 |
| 2026-08-14 | $14.34 | $16.65 | $13.50 | $14.78 | $14.78 | +0.44 | 37,200 |
| 2026-08-13 | $13.09 | $14.20 | $13.00 | $14.09 | $14.09 | +1.00 | 81,000 |
| 2026-08-12 | $13.00 | $13.88 | $12.95 | $13.00 | $13.00 | 0.00 | 684,000 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 8-K | Aug 19, 2026 | Current Report |
| 8-K | Aug 13, 2026 | Current Report |
| S-8 | Aug 13, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Aug 12, 2026 | Prospectus |
| EFFECT | Aug 11, 2026 | Notice of Effectiveness |
| CERT | Aug 11, 2026 | Certification by an exchange approving securities for listing |
| 8-A12B | Aug 10, 2026 | Registration of securities |
| S-1/A | Aug 10, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1/A | Jul 29, 2026 | [Amend] General form for registration of securities under the Securities Act of 1933 |
| S-1 | Jul 15, 2026 | General form for registration of securities under the Securities Act of 1933 |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
James Green
President, Chief Executive Officer and Director
William Wilkison, Ph.D.
Chief Scientific Officer and Director
Steven Delmar
Chief Financial Officer, Corporate Secretary and Director
Timothy Boris
Director
Richard Gorman
Director
Peter Pieraccini
Director
